guidance on what might constitute a core course, but argued Introduction that the fine detail needed to be left to local discussion. The GMC also suggested that specialist groups might define the Medical school curricula are rapidly changing across the UK in response to the calls from the General Medical Council core content of courses [1] . These gave an impetus to the development of a core (GMC) for a more student centred approach [1] . This approach should place less emphasis on acquisition of curriculum for the UK, for which the American core curriculum might provide a useful starting point. A further knowledge and more on establishing lifelong patterns of self directed learning. Such new courses are less subject based impetus to this approach was given by the establishment of a review committee of the Royal College of Physicians to than traditional courses, which may lead to concern on the part of traditional teachers that their subject is no longer review the current status and role of clinical pharmacology and therapeutics in the UK. A working party of the considered important or even relevant.
The GMC identified the 'principles of therapy' as a key committee of the Because of time constraints, this study was conducted by a Delphi questionnaire administered by post and fax. A survey in 1993 showed that few academic clinical pharmacologists in the UK were preparing to adapt to the The Delphi technique [6, 7] is a method for structuring group communication such that individuals within a challenges of the new curricula, and many had significant fears for the future of the subject [3] . To address the group can deal with complex problem, and in particular come to a consensus ( Figure 1 ). The method involves currently poor standing of clinical pharmacology and therapeutics in many medical schools and to support this developing a questionnaire which is sent to each participant, asking them to agree or disagree with each point, and subject in the transition into the new curricula, many academic clinical pharmacologists felt that the definition of encouraging free text comments. Those items for which there is a high degree of consensus (75% or more in this a core course in clinical pharmacology and therapeutics, i.e. the essential principles that every medical student should study) are considered resolved, either to be accepted or rejected. Where there is less agreement, the study master before registration, would be useful.
This approach was taken in the United States where it co-ordinator develops a new questionnaire, rephrasing the questions in accordance with the comments made by the was perceived that clinical pharmacology and therapeutics would be weaker if there was no agreement among clinical respondents; the respondents are then asked to comment again. This iterative process of establishing a question and pharmacologists about what they should teach as a core: if such a core could not be defined, perhaps, it might be modifying or repeating it is continued until consensus is achieved to either accept or reject the point at issue. argued, it did not exist [4] . Accordingly, a consensus derived core curriculum was developed and published [5] . In the Participants are also reminded of the areas in which consensus had been achieved in previous rounds. The title 1993 UK survey, heads of academic departments of clinical pharmacology and therapeutics were asked to comment on of the method comes from the oracle at Delphi in ancient Greece who answered questions either ambiguously or with what aspects of this American model they thought important. Many commented that the American model was further questions. Participants should be experts in the broad subject under inappropriate for the UK and that a specific UK model was needed. Many were supportive of the idea of a central broad consideration, ideally with a range of views covering all major stake holders. Discussion outside the Delphi process is discouraged and the participants are not identified to Concerning the delivery of the course, it was agreed that Study design the best model was a single integrated course starting with basic pharmacology and increasingly involving clinical The starting point for the current study was a questionnaire modified from the American core curriculum in clinical pharmacology and later therapeutics. Elements of all three should be present at most points but with the emphasis pharmacology [4] , which had previously been used in the survey of departments of clinical pharmacology [3] .
moving towards the clinical in the later stages. It was also agreed that the course was best delivered in small amounts Participants were asked to include other items which they felt were not covered by this document, and to make other over the whole of the medical school course, possibly with specific blocks in addition to consolidate general points broad statements about the teaching of clinical pharmacology and therapeutics.
made elsewhere. This model lends itself well to the new problem based curricula developed in some universities. The participants in this study were all senior academic clinical pharmacologists, active in the teaching of clinical A key issue was who should direct the learning of the details of the pharmacology and clinical pharmacology of pharmacology and therapeutics in the UK or Ireland, and were chosen for their experience and interest in education, individual drugs and the therapeutics of major clinical conditions, an area in which competency of the newly and for their willingness to provide speedy replies to the questionnaire. Eight were invited to participate and all qualified doctor is of great importance. In many schools, there simply would not be enough clinical pharmacologists agreed.
The penultimate document was sent to all participants to undertake this task, which is often done by clinical subject specialists. It was agreed that while the directing of and to all heads of departments of clinical pharmacology (where they existed) or to those responsible for teaching the learning in these topics by clinical pharmacologists might be an ideal, it is one which we may be unable to achieve. clinical pharmacology in medical schools across the UK and Ireland, and to the Committee of Heads of Pharmacology
The agreed recommendation is therefore that clinical pharmacologists should be involved in defining the course for final comment and to check face validity. No new points could be added or deleted at this point, but minor changes content in all of these topics and co-ordinating its delivery, but not necessarily involved in directing or delivering it all. to clarify meaning were made in the light of comments received.
The American curriculum was intended to build on a course on the pharmacology of major drug groups. It seems unlikely that such separate courses are sustainable in the Results UK, but we are keen to recognise the important contribution of basic pharmacologists in the training of medical students. The study ran for four rounds before a penultimate document was produced. Seven experts participated in all
Rather than include a range of issues of basic pharmacology, the curriculum simply includes a single summary statement four rounds and one in three. The final version was drafted after receiving further comments on the penultimate version of the basic knowledge which a student must acquire in order to achieve competency in the other areas of the from a further 12 respondents.
The resulting detailed course is presented as a separate curriculum. document [8] . It follows the outlines proposed by the GMC [1] in defining knowledge, skills and attitudes. This division Discussion is useful for describing the core content, but in clinical practice, elements of all three merge to form competencies The Delphi technique is particularly suitable to address certain types of issue: where the question does not lend and will therefore be learned simultaneously.
Developing a core curriculum itself to precise analytical techniques but can benefit from wider audience would be useful in defining how clinical pharmacology can help to meet the educational needs of collective subjective judgements; where timing and cost make frequent group meetings difficult or impossible; where this audience. This was not possible within the time constraints of the current study. likely disagreements make it essential that the communication process be refereed and anonymity assured; and where the The document is also lacking in detail about the assessment of the core content. Such assessment will undoubtedly heterogeneity of the participants is important to ensure the validity of the results [6] . It facilitates the convergence of remain an important part of the student's life and will to some extent shape the course. Since the development of opinion by providing structured feedback in the form of statistical information to the participants and structures competencies (i.e. the knowledge, skills and attitudes that the student should learn in order to become competent to the debate so as to keep the participants focused on the topic. The technique was therefore particularly suitable for prescribe drugs safely and effectively and to maintain this competence throughout their professional life) is the main this study on several points, particularly given the variety of experience across the country from different medical schools.
aim of the course, its assessment must reflect the same emphasis. How best to test such competencies is uncertain The strengths of the defined course are that it is a comprehensive definition of what a core course in clinical and will require further discussion and development. Finally, it is important that this core content be reviewed pharmacology and therapeutics should include. It is deliberately generic, and not prescriptive; it aims to establish only in the light of its use, and then appropriately modified to ensure that it meets the needs of the medical profession as a what the principle elements of a course should be, with the intention that these can be incorporated in a variety of ways whole. This argues again for development of the core content by more than just academic clinical pharmacologists, into the curriculum in different medical schools. Integration of such a core content into the overall core curriculum is but also recognises the changing nature both of medicine (for example, the move to a primary care led health service essential: an example of an approach to integrating a similar curriculum into a newly developing problem based course in the UK) and of medical education.
Other disciplines have also felt a need to define a core in one medical school has recently been described [9] .
However it is to be integrated, any new course needs to content [12] [13] [14] [15] [16] [17] . Our proposals for clinical pharmacology and therapeutics are more detailed than most. All consider be more student centred or competency centred than the older teacher and subject centred courses in the past [10] .
that insufficient emphasis is currently placed on the discipline, or that the discipline will suffer in the newer curricula. The document therefore emphasises learning rather than teaching, and does not address in detail how the learning in While this may sound like specialists making special pleading for their own discipline, in most cases it seems appropriate. these elements should be directed, as this will differ among medical schools. We believe that much of the curriculum Many represent areas of great importance because of the burden they impose on patients or to the health service, but can only be learned effectively in parallel with clinical 'bedside' studies.
which were up to now poorly represented in the traditional medical curricula, dominated by 'interesting' hospital based The document has weaknesses also: firstly it is a consensus, which is sometimes described as where everyone agrees diseases, or by strong university departments. The establishment of core courses in these previously under-emphasised what no one actually believes individually. As such, a number of issues considered important by some were areas will go some way to redress the balance. Clinical pharmacologists should now direct their efforts eliminated or heavily modified in the consensus process, including for instance pharmacoeconomics, detailed pharmto ensuring that no student leaves medical school without adequately mastering this core. This should allow the student acokinetics and detailed dose calculations. Some may be disappointed that it does not stridently argue for an increased to prescribe drugs in a way that increases effectiveness while minimising harm, and if the principles are reinforced role of academic clinical pharmacologists, but after much discussion, the consensus view was that clinical pharmacolperiodically, to go on doing so for the rest of his professional life, despite the likelihood of rapid changes in drug therapy ogists need to accept that the expansion in the discipline which would allow this to occur is unlikely. Even the in the future. modest role advocated in the document, i.e. involvement
The participants in the Delphi study were: Dr J. Aronson, in the definition of the necessary learning in therapeutics Oxford, Professor D. Barnett, Leicester, Dr N. Bateman, and the use of drugs in major clinical conditions, would be Newcastle, Professor J. Feely, Dublin, Professor C. George, an important new development in some schools.
Southampton, Professor P. Vallance, London, Dr D. Waller, A further weakness is that the document has been Southampton and Professor D. Webb, Edinburgh. Professor developed by academic clinical pharmacologists who may T. Walley was the study co-ordinator. have a narrow focus and who are particularly likely to concentrate on secondary care. This may prevent them from References fully appreciating the needs of doctors in primary care, who prescribe over 90% of all drugs in the UK: there have been
